Use of glucose sensor (Paradigm Guardian)
DeviceUse glucose sensor to prevent episodes of severe hypoglycemia
Other names: Paradigm Guardian glucose sensor
NCT Number: NCT00554281
Hypoglycemia is the most common complication of Type 1 diabetes particularly in those who strive for good glycemic control. In some patients there is a loss of awareness of hypoglycaemia so that the first manifestation of hypoglycaemia may be confusion or coma. Such a situation may carry risks that the patient may harm him or her self. Medtronic has recently developed a continuous glucose sensor that determines the glucose level every 3 minutes using a subcutaneous sensor and transmits the information to a remote device (Paradigm RT) that may be worn or left close by eg on a bedside table. The device may be programmed to alarm for a rapidly falling glucose or for low glucose levels.
We propose to use this in 16 patients with severe hypoglycemia as evidenced by a high HYPO score and see if we can decrease the number of hypoglycemic reactions and document this improvement with a better HYPO score.
Looking for future studies?
Notify Me18 year–70 year
All sexes
Interventional
Phase 3
University of Alberta, Edmonton, Alberta, Canada
Sixteen patients with Type 1 diabetes (as defined by: onset under the age of 25, lean at time of onset, continuous insulin use, and/or history of ketoacidosis and C-peptide negative), with a HYPO score over the seventy-fifth percentile (>423), will be approached and offered the study.
The study will be conducted over a three month time-frame. The first month will be a run-in period for participants to collect four weeks of glucose readings and information about their hypoglycemic events. These records will be used to calculate the baseline modified HYPO score. Patients will be screened during the first month for thyroid disease, celiac disease and Addison's disease.
During the second month they will meet with the study nurse for an intensive instruction period on the use of the Paradigm RT sensor. They will spend this month practicing to use the sensor and confirming they can use it adequately.
During the final month they will wear the sensor and collect glucose and hypoglycemia records for calculation of the final modified HYPO score.
The end point will be the change from the baseline modified HYPO score to the final four week HYPO score and this would be used to identify any improvement.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Use glucose sensor to prevent episodes of severe hypoglycemia
Other names: Paradigm Guardian glucose sensor
Time frame: 3 months
Time frame: 3 months
Time frame: 3 months
University of Alberta
Other
Paradigm Real Time Continuous Glucose Monitoring Device for the Prevention of Hypoglycemia
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT04614168
Autoimmune Diseases, Diabetes Mellitus
Edinburgh, United Kingdom
View Trial DetailsNCT05616273
Autoimmune Diseases, Diabetes Mellitus
Exeter, Devon, United Kingdom
View Trial DetailsNCT05379686
Autoimmune Diseases, Behavior
Herlev, Denmark
View Trial DetailsNCT05378672
Autoimmune Diseases, Diabetes Mellitus
Atlanta, Georgia, United States
View Trial Details